Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Prostatic Neoplasms 47Glioblastoma 47Breast Neoplasms 40Esophageal Neoplasms 36Rectal Neoplasms 35Carcinoma, Non-Small-Cell Lung 34Lung Neoplasms 33Head and Neck Neoplasms 29Squamous Cell Carcinoma of Head and Neck 26Brain Neoplasms 23Pancreatic Neoplasms 22Neoplasms 19Uterine Cervical Neoplasms 17Oropharyngeal Neoplasms 16Neoplasm Metastasis 16Gliosarcoma 16Esophageal Squamous Cell Carcinoma 16Glioma 15Sarcoma 14Melanoma 14Stomach Neoplasms 12Adenocarcinoma Of Esophagus 12Lymphoma, Follicular 9Carcinoma, Squamous Cell 9Mouth Neoplasms 8Lymphoma, B-Cell, Marginal Zone 8Anus Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Leukemia, Myeloid, Acute 7Endometrial Neoplasms 7

Interventions

Gemcitabine 58Cisplatin 41Capecitabine 27Oxaliplatin 25durvalumab 16Fluorouracil 16Leucovorin 15S 1 (combination) 11lenvatinib 10Nivolumab 10Irinotecan 10pembrolizumab 8apatinib 8Immune Checkpoint Inhibitors 7130-nm albumin-bound paclitaxel 7tremelimumab 6Bevacizumab 6camrelizumab 5Trastuzumab 5Drug Therapy 5Blood Specimen Collection 5Albumin-Bound Paclitaxel 5tislelizumab 4irinotecan sucrosofate 4Taxes 4Liquid Biopsy 4Folfox protocol 4toripalimab 3surufatinib 3gemcitabine-oxaliplatin regimen 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Biliary Tract Neoplasms × Radiation × Clear all
NCT03482102 2026-05-04

Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer

Massachusetts General Hospital

Phase 2 Active not recruiting
37 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡